Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Apellis Pharmaceuticals, Inc. - Common Stock (NQ:APLS)

17.67 +0.22 (+1.26%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Apellis Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
Deep Dive Into Apellis Pharmaceuticals Stock: Analyst Perspectives (20 Ratings)
Via Benzinga
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
A Glimpse Into The Expert Outlook On Apellis Pharmaceuticals Through 20 Analysts
Via Benzinga
A Glimpse of Apellis Pharmaceuticals's Earnings Potential
Via Benzinga
The Latest Analyst Ratings For Apellis Pharmaceuticals
Via Benzinga
Navigating 18 Analyst Ratings For Apellis Pharmaceuticals
Via Benzinga
Analyst Scoreboard: 15 Ratings For Apellis Pharmaceuticals
Via Benzinga
Energizer, C3.ai, Insmed And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Apellis Pharmaceuticals to Host a Fireside Chat at the Jefferies London Healthcare Conference
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Lululemon To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Wednesday
Via Benzinga
Why Apellis Pharmaceuticals Stock Was Tumbling on Tuesday
Sales of the company's top commercialized product didn't meet expectations. 
Via The Motley Fool
Apellis Pharmaceuticals Dives On Worse-Than-Expected Syfovre Sales
The company is best known for its drug, Syfovre, a treatment for geographic atrophy. 
Via Investor's Business Daily
Celanese Posts Downbeat Results, Joins Cirrus Logic, Teradata And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Apellis Pharmaceuticals Reports Third Quarter 2024 Financial Results
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
1 Nasdaq Stock Down 62% This Year That Could Double Your Money, According to a Wall Street Analyst
It has been a rotten year for Apellis Pharmaceuticals stock, but better times could be ahead. 
Via The Motley Fool
Pivotal VALIANT Results Presented at Kidney Week Highlight Strength of Pegcetacoplan Treatment Effect in Patients with C3G / Primary IC-MPGN
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Apellis Pharmaceuticals to Host Conference Call on November 5, 2024, to Discuss Third Quarter 2024 Financial Results
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Syfovre's Competitive Edge Highlights Bright Future For Apellis Pharmaceuticals, Analyst Initiates With Bullish Pitch
William Blair initiates coverage of Apellis Pharmaceuticals, highlighting its innovative therapies for complement C3 targeting. The analyst forecasts significant growth opportunities with peak sales... 
Via Benzinga
Apellis Announces Oral Presentation at American Society of Nephrology (ASN) Kidney Week on Phase 3 VALIANT Study of Pegcetacoplan in C3G and Primary IC-MPGN
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Apellis Pharmaceuticals to Host a Fireside Chat at the UBS Virtual Ophthalmology Day
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
CrowdStrike To Rally Over 15%? Here Are 10 Top Analyst Forecasts For Monday
Via Benzinga
What's Going With Apellis Pharmaceuticals Stock Friday?
Apellis Pharmaceuticals shares are moving lower after the Committee for Medicinal Products for Human Use of the European Medicines Agency confirmed its June 2024 negative opinion following... 
Via Benzinga
Apellis Stock Hammered After Eye Drug Gets A Third European Rejection
The company is "out of European approval options" for its embattled geographic atrophy drug, says one analyst. 
Via Investor's Business Daily
Apellis Receives Negative CHMP Opinion for Pegcetacoplan for Geographic Atrophy (GA) in the EU Following Re-Examination
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Wedbush Just Raised its Price Target on These 7 Stocks: August 12, 2024
New Wedbush price targets have been issued for each of the following seven stocks, including a few that may come as a surprise to some. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.